UnitedHealth Group will report third-quarter results before the market opens on Tuesday 13 October and host an analyst call at 8:00 a.m. ET, the company said in a 15 September announcement. TipRanks puts consensus at $4.15 a share on revenue of $111.31 billion. MarketBeat has $4.12 on about $111.3 billion. Both are aggregators, and neither is a company forecast. A year ago the company earned $2.92 a share on an adjusted basis, TipRanks notes.
The earnings per share is not the interesting number. The medical care ratio, and what the company says about the rest of the year, are.
What the company has already said
On 16 July UnitedHealth reported second-quarter adjusted earnings of $6.38 a share on revenue of $112.0 billion. The medical care ratio, the share of premiums paid out in care, was 86.7 per cent, against 89.4 per cent a year earlier. The company raised its 2026 adjusted earnings range to $19.50 to $20.00 a share, from the "greater than $18.25" it set in its April release. Its outlook table puts the full-year medical care ratio at 88.1 per cent, plus or minus 25 basis points.
The first quarter ratio was 83.9 per cent and first-quarter adjusted earnings were $7.23. Put those next to the full-year figure and the arithmetic is awkward.
The second half the guidance implies
By this publication's arithmetic, first-half adjusted earnings were $13.61 a share. A full-year range of $19.50 to $20.00 leaves $5.89 to $6.39 for the second half. If the third quarter comes in at the $4.15 TipRanks expects, the fourth would need to deliver roughly $1.74 to $2.24. MarketBeat puts full-year consensus at about $20, the top of the company's range.
The ratio tells the same story. Averaging 88.1 per cent over four quarters, after 83.9 and 86.7, requires about 90.4 to 91.4 per cent across the last two. That assumes equal premium weight in each quarter, which is an approximation. It is still a rise of roughly four points from the second quarter. That is our derivation, not a figure the company has published.
How much the second quarter was flattering
The second-quarter ratio included $860 million of net favorable prior-period development, the company said, "with the majority related to 2026 dates of service." Costs in the current year ran below what had been set aside. That is better than a release of old reserves, but it still lowered the reported ratio.
Spread over $112.0 billion of total revenue, $860 million is about 0.8 points. Over the $86.0 billion UnitedHealthcare reported, it is about 1.0 point. Either way, the underlying second-quarter ratio was closer to 87.5 or 87.7 per cent. That is our estimate, and the premium base is a rough one.
Sensitivity is the point. Using the company's guided tax rate of about 18.5 per cent and its 906 million diluted shares, one point of ratio on UnitedHealthcare's revenue is worth about $0.77 a share in a quarter. Against a $4.15 consensus, that is roughly a fifth of the quarter.
Where Medicare Advantage fits
The company's headline ratio does not isolate Medicare Advantage, so the product-level cost trend will have to come from the call. Star ratings are a separate pressure: J.P. Morgan estimates the share of UnitedHealth's members in plans rated four stars or more for 2027 will fall to about 67 per cent from 81 per cent, Reuters reported, while Humana's has jumped. Those ratings set bonus payments in 2028. UnitedHealthcare served 48.5 million people in the second quarter, 525,000 fewer than in the first, and earned an operating margin of 4.6 per cent against 2.4 per cent a year earlier.
Analysts quoted by TipRanks are not aligned on the risks. TD Cowen's Ryan Langston called third-quarter consensus for medical costs and earnings "more than achievable," but warned that lower Medicare Advantage star ratings could cost $1.5 billion of revenue in 2028. Piper Sandler's Jessica Tassan, who cut her price target, wrote: "We would be buyers of the stock into 3Q26." TipRanks reports Langston also sees upside at Optum Health, where he cites consensus operating earnings of $299 million against management guidance of about $150 million.
What happens next
TipRanks says options are pricing a move of 7.15 per cent in either direction, about $27.12 a share. The stock's last four post-earnings moves ranged from a 19.61 per cent fall to a 6.96 per cent gain, it reports.
Three tests will settle the reading above. First, whether the third-quarter ratio lands near the roughly 90 per cent the guidance implies for the back half, or well below it. We did not find a published consensus for the quarter's ratio. Second, whether the company holds, narrows or raises the $19.50 to $20.00 range when the Street already sits at the top of it. Third, whether it reports reserve development again, and how large. A clean quarter with a flat outlook would leave little for the shares to rise on. A lower third-quarter ratio with no change to the full-year figure would suggest the fourth quarter is carrying the caution.
The date, time and call details come from UnitedHealth Group's 15 September 2026 announcement. Second-quarter figures (adjusted earnings of $6.38 a share, revenue of $112.0 billion, medical care ratio of 86.7 per cent against 89.4 per cent a year earlier, $860 million of net favorable prior-period reserve development, 48.5 million people served, outlook of $19.50 to $20.00 adjusted and a medical care ratio of 88.1 per cent plus or minus 25 basis points) come from the company's 16 July 2026 release. First-quarter figures (adjusted earnings of $7.23, medical care ratio of 83.9 per cent, April outlook of more than $18.25) come from its 21 April 2026 release. Consensus figures, the options-implied move of 7.15 per cent, the $2.92 year-earlier comparison and the TD Cowen and Piper Sandler comments come from TipRanks (11 October 2026); the $4.12 estimate and the roughly $20 full-year consensus come from MarketBeat (6 October 2026). These are aggregators, and the consensus numbers are theirs, not ours. TipRanks describes its $113.20 billion revenue comparator as the prior quarter, which does not match the $112.0 billion the company reported for the second quarter, so we have not used it. This publication's arithmetic: first-half adjusted earnings of $13.61 ($7.23 plus $6.38); implied second-half earnings of $5.89 to $6.39; implied fourth-quarter earnings of $1.74 to $2.24 against a $4.15 third quarter; an implied second-half medical care ratio of 90.4 to 91.4 per cent, which assumes the four quarters carry equal weight in the annual ratio; a reserve-release effect of 0.8 to 1.0 percentage points, using $112.0 billion of total revenue and $86.0 billion of UnitedHealthcare revenue as rough bounds on the premium base; and about $0.77 a share per point of ratio, using the company's roughly 18.5 per cent tax-rate guidance and 906 million diluted shares in the second quarter. The diluted share count, tax-rate guidance, UnitedHealthcare revenue, membership and margin figures are from the 16 July release. A brief for this story cited Financial Modeling Prep; we could not open that page and it is not used. The UnitedHealth Group Q3 date page is a primary source; all other estimates are attributed. The consensus medical care ratio for the quarter was not in the sources we reviewed. The analysis is our own.
Topics healthmarketsUnitedHealthMedicare Advantageearnings preview
